zorevunersen (STK-001)
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome
Trial Timeline
Jan 20, 2021 → Mar 31, 2029
NCT ID
NCT04740476About zorevunersen (STK-001)
zorevunersen (STK-001) is a phase 2 stage product being developed by Stoke Therapeutics for Dravet Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT04740476. Target conditions include Dravet Syndrome.
What happened to similar drugs?
2 of 12 similar drugs in Dravet Syndrome were approved
Approved (2) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04740476 | Phase 2 | Active |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 32 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 29 |
| fenfluramine | UCB | Approved | 50 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 26 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| fenfluramine | UCB | Phase 3 | 44 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| Clobazam | Lundbeck | Phase 3 | 29 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 29 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 47 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 41 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 26 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 41 |